DelveInsight’s “Idiopathic Pulmonary Fibrosis Pipeline Insight” report provides comprehensive insights about key companies and pipeline drugs in the Idiopathic Pulmonary Fibrosis pipeline landscapes.
The report comprises Idiopathic Pulmonary Fibrosis pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Idiopathic Pulmonary Fibrosis therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Idiopathic Pulmonary Fibrosis pipeline products.
Some of the key takeaways from the Idiopathic Pulmonary Fibrosis Pipeline Report:
Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players, such as FibroGen, Kadmon Corporation, Promedior, Galapagos, MediciNova, etc., are developing therapies for the treatment of Idiopathic Pulmonary Fibrosis.
Emerging therapies such as Pamrevlumab, KD025, PRM-151, GLPG1690, Tipelukast, are expected to have a significant impact on the Idiopathic Pulmonary Fibrosis market in the coming years.
Get an overview of pipeline landscape @ Idiopathic Pulmonary Fibrosis Clinical Trials Analysis
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive disease characterized by the aberrant accumulation of fibrotic tissue in the lungs, associated with significant morbidity and poor prognosis. It is the most common form of fibrosing idiopathic interstitial pneumonia, is an inexorably progressive disease with a 5-year survival of ~20%.
Idiopathic Pulmonary Fibrosis Pipeline Therapies along with Key Players:
Pamrevlumab by FibroGen,
KD025 by Kadmon Corporation,
PRM-151 by Promedior,
GLPG1690 by Galapagos,
Tipelukast by MediciNova,
And others.
Scope of Idiopathic Pulmonary Fibrosis Pipeline Drug Insight
Coverage: Global
Major Players: FibroGen, Kadmon Corporation, Promedior, Galapagos, MediciNova, and others.
Pipeline Therapies: Pamrevlumab, KD025, PRM-151, GLPG1690, Tipelukast, and others.
Table of Contents
1
Idiopathic Pulmonary Fibrosis Report Introduction
2
Idiopathic Pulmonary Fibrosis Executive Summary
3
Idiopathic Pulmonary Fibrosis Overview
4
Idiopathic Pulmonary Fibrosis- Analytical Perspective In-depth Commercial Assessment
5
Idiopathic Pulmonary Fibrosis Pipeline Therapeutics
6
Idiopathic Pulmonary Fibrosis Late Stage Products (Phase II/III)
7
Idiopathic Pulmonary Fibrosis Mid Stage Products (Phase II)
8
Idiopathic Pulmonary Fibrosis Early Stage Products (Phase I)
9
Idiopathic Pulmonary Fibrosis Preclinical Stage Products
10
Idiopathic Pulmonary Fibrosis Therapeutics Assessment
11
Idiopathic Pulmonary Fibrosis Inactive Products
12
Company-University Collaborations (Licensing/Partnering) Analysis
13
Idiopathic Pulmonary Fibrosis Key Companies
14
Idiopathic Pulmonary Fibrosis Key Products
15
Idiopathic Pulmonary Fibrosis Unmet Needs
16
Idiopathic Pulmonary Fibrosis Market Drivers and Barriers
17
Idiopathic Pulmonary Fibrosis Future Perspectives and Conclusion
18
Idiopathic Pulmonary Fibrosis Analyst Views
19
Appendix
20
About DelveInsight
Related Reports:
Idiopathic Pulmonary Fibrosis Market
DelveInsight’s ‘Idiopathic Pulmonary Fibrosis (IPF) – Market Insights, Epidemiology, and Market Forecast-2030 report deliver an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of IPFs in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Idiopathic Pulmonary Fibrosis Epidemiology
DelveInsight’s Multiple Myeloma – Epidemiology Forecast to 2030 report delivers an in-depth understanding of the disease, historical and forecasted Multiple Myeloma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kritika RehaniEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/